EPHA3 and cancer: Next-generation sequencing of lung cancer patient tumors has identified numerous putative new cancer drivers, including EPH (also defined as erythropoietin-producing hepatocellular) receptor A3 (EPHA3), which is mutated in 6–16% of lung ADC samples (Cancer Genome Atlas Research Network, 2014; Ding et al., 2008; Imielinski et al., 2012).